Skip to main content

efdelikofusp alfa

Generic: Efdelikofusp Alfa

efdelikofusp alfa: 1 clinical trial tracked.

efdelikofusp alfa evidence translation

What we can confirm

1 tracked trial

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about efdelikofusp alfa, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (1)

A Phase 1/2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101/GI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)

NCT04977453Registry updated 2026-09-14·Phase 1/Phase 2
Recruiting

Primary endpoint: Incidence and nature of Dose-Limiting Toxicity (DLTs), Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs)

Interventionalopen317 targetStarted 2021-08Completion 2028-0613 sites · South Korea, United StatesGI Innovation, Inc.